Peptides for Weight Loss: Which Are FDA-Approved, and Which Are Not?

Peptides for weight loss are medicines made of short chains of amino acids that act like the body's own appetite and blood sugar hormones. As of November 2026, four peptides are FDA-approved for weight management: semaglutide (Wegovy®), tirzepatide (Zepbound®), liraglutide (Saxenda®) and setmelanotide (Imcivree®, only for certain rare genetic or hypothalamic causes of obesity). No other peptide is FDA-approved for weight loss. Retatrutide and cagrilintide are still in clinical trials, and BPC-157, AOD-9604, CJC-1295, ipamorelin and MOTS-c are not approved for any use. The FDA urges consumers not to buy products labeled "for research purposes" or "not for human consumption."

The rules around unapproved peptides did change in 2026. In April, the FDA took 12 peptides off its "significant safety risks" list after their nominations were withdrawn. In July, an FDA advisory committee voted narrowly to recommend six of the seven peptides it reviewed for pharmacy compounding. On October 30, the Department of Health and Human Services (HHS) published a draft enforcement policy saying it does not intend to take action against licensed pharmacies that compound certain peptides. None of these steps is an FDA approval, and none applies to "research use only" vials.

If you want a peptide with strong weight-loss evidence, semaglutide and tirzepatide lead. A licensed provider can prescribe the brands or a compounded version. Through MaxLife, compounded semaglutide is $89 a month and compounded tirzepatide is $120 a month, flat. Compounded medicines are not FDA-approved, a licensed provider decides whether one is right for you, and MaxLife does not offer research peptides or any of the unapproved peptides in this guide.

What Are Peptides for Weight Loss?

A peptide is a short chain of amino acids, the building blocks of proteins. Federal rules draw the line at 40: a chain of more than 40 amino acids counts as a protein (21 CFR 600.3). Many hormones are peptides, including GLP-1 (glucagon-like peptide-1) and GIP, which your gut releases after you eat to help control appetite and blood sugar.

Most weight-loss peptides are lab-made versions of those hormones, changed so they last longer in the body:

• Semaglutide copies GLP-1. The Wegovy label says its "peptide backbone is produced by yeast fermentation."
• Tirzepatide acts on both the GIP and GLP-1 receptors. It is a 39-amino-acid peptide, as our guide to whether tirzepatide is a peptide explains.
• Liraglutide is "97% homologous to native human GLP-1," per the Saxenda label, and is injected once a day.
• Setmelanotide is "an 8 amino acid cyclic peptide" that acts on a brain receptor (MC4) that controls hunger, according to the Imcivree label.
• Cagrilintide, still in trials, copies amylin, another hormone that helps you feel full.

"Peptide" describes how a molecule is built, not whether it is approved, safe or effective. A Wegovy pen and a vial of BPC-157 are both peptides; only one has passed FDA review.

Is Ozempic a Peptide? Is Every Peptide a GLP-1?

Yes, Ozempic® is a peptide medicine. Its active ingredient is semaglutide, which is also the active ingredient in Wegovy. But Ozempic is FDA-approved for type 2 diabetes (first approved December 5, 2017), not for weight loss. Wegovy is the semaglutide brand approved for weight management. Tirzepatide also has two brands: Mounjaro® is approved for type 2 diabetes (May 13, 2022) and Zepbound for weight management.

Peptides and GLP-1s are not the same thing. GLP-1 medicines are one group of peptides. Many peptides sold online, such as BPC-157 or CJC-1295, don't act on the GLP-1 receptor at all.

Which Peptides Are FDA-Approved for Weight Loss?

Four peptides are in FDA-approved weight-management medicines, as of November 2026:

Sources: Drugs@FDA approval records and the current labels on DailyMed, checked November 2026.

Here is what each brand's label reports from its main trials:

• Zepbound: in SURMOUNT-1, adults lost an average of 15.0%, 19.5% and 20.9% of their body weight on 5 mg, 10 mg and 15 mg over 72 weeks, versus 3.1% on placebo (Zepbound label).
• Wegovy injection: 14.9% versus 2.4% on placebo at 68 weeks with 2.4 mg, and 18.8% versus 3.9% at 72 weeks with the 7.2 mg dose. Wegovy tablets: 13.6% versus 2.4% at 64 weeks.
• Saxenda: 7.4% versus 3.0% on placebo at 56 weeks, with a daily injection.
• Imcivree: in acquired hypothalamic obesity, body mass index fell 18.4% more than with placebo after 52 weeks. In POMC or PCSK1 deficiency, 80% of patients lost at least 10% of their weight in a year (46% in LEPR deficiency). The label says it is not for common (polygenic) obesity.

These results belong to the brand medicines studied. They have not been shown for compounded semaglutide or compounded tirzepatide.

Which Weight Loss Peptides Are Not FDA-Approved?

Every other peptide sold or promoted for weight loss lacks FDA approval for that use. Here is where each one stands:

Sources: Drugs@FDA, the FDA's compounding pages (April and May 2026), the FDA's GLP-1 statement and the Federal Register.

Retatrutide and Cagrilintide: Still in Trials

Retatrutide is Eli Lilly's investigational weekly injection that acts on three hormone receptors (GIP, GLP-1 and glucagon). In the phase 3 TRIUMPH-1 trial, published in November 2026, adults on the highest dose lost 25.0% of their body weight over 80 weeks, versus 3.9% on placebo. It is not approved anywhere, and Lilly plans to submit it to the FDA in the first quarter of 2027. Our comparison of retatrutide vs tirzepatide covers every trial.

Cagrilintide is Novo Nordisk's investigational amylin analog. Combined with semaglutide as CagriSema, it produced 20.4% weight loss versus 3.0% on placebo at 68 weeks in the REDEFINE 1 trial (NEJM, 2025). Novo filed CagriSema with the FDA on December 18, 2025. As of November 10, 2026, the FDA's drug database lists no approved product containing cagrilintide. Cagrilintide on its own is in phase 3 trials (RENEW) that ClinicalTrials.gov lists with primary completion estimated for May 2027.

Neither can be compounded. The FDA states: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition."

Tesamorelin: Approved, but Not for Weight Loss

Tesamorelin (Egrifta) is a lab-made version of growth hormone-releasing factor, first approved on November 10, 2010. Its current label limits it to "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy" and states that it "is not indicated for weight loss management as it has a weight neutral effect." So tesamorelin is an approved peptide, but not a weight-loss peptide.

What the FDA Says About BPC-157, AOD-9604, CJC-1295, Ipamorelin and MOTS-c

None of these peptides has ever been approved by the FDA for any use. The FDA's page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) gives its reasons for concern:

• BPC-157: the FDA "has identified no, or only limited, safety-related information for the proposed routes of administration."
• MOTS-c: the FDA "has not identified any human exposure data on drug products containing MOTs-C."
• AOD-9604: the FDA "has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear."
• CJC-1295: the FDA "has identified serious adverse events associated with CJC-1295 including increased heart rate."
• Ipamorelin: "A study published in literature identified serious adverse events including death." Ipamorelin is still on the FDA's significant-risk list for outsourcing facilities.

For each one, the FDA also warns of possible immunogenicity, meaning your immune system may react against the peptide, and of impurities that are hard to detect. At the July 2026 advisory meeting, FDA reviewers said the studies of the peptides under review were too small and short to establish their safety or effectiveness, according to AJMC.

Is Foundayo a Peptide?

No. Foundayo™ (orforglipron), the GLP-1 weight-loss pill the FDA approved on April 1, 2026, is a small molecule, not a peptide. Wegovy tablets, by contrast, contain the semaglutide peptide.

What Changed for Peptides in 2026?

Three federal steps in 2026 eased the path for some unapproved peptides to be compounded by pharmacies. None of them made a peptide FDA-approved:

• April 2026: the FDA's "significant safety risks" list. The FDA sorts ingredients that pharmacies have asked to compound into categories. Category 1 means "may be eligible"; category 2 means the FDA "has identified significant safety risks." After their nominators withdrew them, 12 peptides came off category 2, including BPC-157, MOTS-c and TB-500. The FDA's list updated May 14, 2026 shows they are not in category 1 either.
• July 23 and 24, 2026: an advisory vote. The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides, including BPC-157 for ulcerative colitis and MOTS-c for "obesity and osteoporosis," per the Federal Register notice. It voted to recommend six of the seven for the list pharmacies can compound from, by close margins (8 to 6 for BPC-157 and 7 to 5 for MOTS-c, as AJMC reported). The FDA's own scientists opposed adding any of them, and the committee's votes are not binding.
• October 30, 2026: a draft HHS policy. HHS said it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance" on its list, while the FDA writes a final rule. Legal analysts report the list has six peptides: BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV. HHS took public comments for two weeks and says it may revisit the policy if "a safety signal or product quality issue arises."

What this means for you:

• It is not an approval. HHS's own notice says compounded drugs "are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed."
• It covers pharmacies, not research sellers. Section 503A, which the policy is about, covers drugs that a state-licensed pharmacy or a licensed physician compounds for an individual patient based on a prescription. It does nothing for vials sold "for research."
• It is not weight-loss evidence. Of the six, only MOTS-c was reviewed for obesity, and the FDA has said it found no human exposure data on drug products containing it.

Compounded semaglutide and tirzepatide follow separate rules, which changed after their shortages ended. Our guide to whether compounded tirzepatide is still legal explains them with dates.

Are "Research Use Only" Peptides Legal or Safe?

No. Peptides sold online "for research use only" or "not for human consumption" are not a legal or safe way to lose weight. The FDA says it has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide "that are falsely labeled 'for research purposes' or 'not for human consumption.'" It adds: "These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."

Common signs of a research product:

• It is sold without a prescription or a review by a licensed provider.
• The label says "research use only," "not for human consumption" or "lab use only."
• It comes as a powder with mixing water and a "peptide calculator," and no pharmacy label with your name on it.

The FDA's advice is simple: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Its BeSafeRx checklist explains how to spot a safe online pharmacy. Our tirzepatide peptide guide shows how the FDA has treated research-labeled GLP-1 vials.

What Is the Best Peptide for Weight Loss?

By the evidence, tirzepatide has produced the most weight loss of any FDA-approved peptide. In the head-to-head SURMOUNT-5 trial, adults on Zepbound lost an average of 20.2% of their body weight at 72 weeks, versus 13.7% on Wegovy 2.4 mg. Our comparison of tirzepatide vs Wegovy covers that trial in detail.

The other approved options rank this way in their own trials (not head to head):

• Wegovy 7.2 mg: 18.8% at 72 weeks, the highest semaglutide result.
• Wegovy 2.4 mg injection or 25 mg tablets: 14.9% at 68 weeks and 13.6% at 64 weeks.
• Saxenda: 7.4%, with a daily injection. Our tirzepatide vs Saxenda guide compares the two.

"Best" also depends on your health, your side effects, your insurance and your budget, so talk to your provider. These results come from Zepbound and Wegovy; they have not been shown for compounded tirzepatide or compounded semaglutide.

Do unapproved peptides work for weight loss? There is no FDA-reviewed evidence that BPC-157, AOD-9604, CJC-1295, ipamorelin or MOTS-c cause meaningful weight loss in people. Retatrutide and CagriSema have strong trial results but are not available outside trials.

Are Weight Loss Peptides Safe? Side Effects and Who Should Avoid Them

The approved peptides have known side effects, listed on their FDA labels. Stomach and bowel effects are the most common:

• Wegovy 2.4 mg: nausea in 44% of adults versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6% and constipation 24% versus 11% (Wegovy label).
• Zepbound: nausea in 25% to 29% of adults versus 8% on placebo, with diarrhea, vomiting and constipation also common.
• Imcivree: skin darkening was the most common reaction in one trial (67% versus 0%), and the label warns about depression and suicidal thoughts.

Who should avoid them? Wegovy, Zepbound and Saxenda carry a boxed warning about thyroid C-cell tumors seen in rodents, and they should not be used if you or a family member has had medullary thyroid carcinoma or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The Zepbound and Wegovy labels say to stop the medicine when pregnancy is recognized. Your provider should review your full health history before you start.

For unapproved peptides, nobody can tell you the risks, because they haven't been studied enough. The FDA lists immune reactions, impurities, a faster heart rate (CJC-1295) and a reported death in a published study (ipamorelin) among its concerns. Some people take very small doses of GLP-1 medicines hoping for fewer side effects; see what the evidence says about microdosing tirzepatide before trying it, and talk to your provider.

How Can You Get a Weight Loss Peptide Legally?

Every legal route starts with a prescription from a licensed provider. There are two:

1. An FDA-approved brand. Insurance may cover Wegovy, Zepbound or Saxenda. Without coverage, as of November 2026, LillyDirect lists Zepbound at $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg when you refill on time. NovoCare lists Wegovy injection at $199 for each of the first two fills for new patients (offer through December 31, 2026), then $349 a month ($399 for Wegovy HD), and Wegovy tablets at $149 to $299 a month.
2. Compounded semaglutide or tirzepatide. A licensed pharmacy prepares the medicine for your prescription. Compounded semaglutide and compounded tirzepatide are not FDA-approved, which means the FDA hasn't reviewed them for safety, effectiveness or quality. The FDA says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug," and your provider makes that call.

What isn't a legal route: unapproved peptides sold "for research," prescription peptides sold without a prescription, and sellers that aren't licensed pharmacies.

How MaxLife Works

MaxLife is a telehealth patient management platform, not a pharmacy or drug maker. You complete an online intake in about 2 minutes. A licensed provider reviews your online intake, health history and clinical records, usually within 24 hours, can follow up with questions, and you can ask for a video visit. If the provider decides a compounded medicine is right for you, licensed partner pharmacies prepare and dispense it.

Compounded semaglutide is $89 a month and compounded tirzepatide is $120 a month, flat. Both prices are all-inclusive and the same at every dose: the provider's review and follow-up, the medicine if prescribed, supplies and free expedited shipping, with no membership fee. No insurance is needed, HSA and FSA funds may be eligible, and MaxLife serves all 50 states, has a Spanish-speaking team and is LegitScript certified. MaxLife does not offer retatrutide, cagrilintide, research peptides or any of the other unapproved peptides in this guide. If your insurance covers a brand, that may be the better route for you.

The Bottom Line

Only four peptides are FDA-approved for weight management as of November 2026: semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda) and, for rare causes of obesity, setmelanotide (Imcivree). Retatrutide and cagrilintide are still investigational. BPC-157, AOD-9604, CJC-1295, ipamorelin and MOTS-c are not approved for any use, and the 2026 changes affect only pharmacy compounding of a few of them, not FDA approval. Skip "research use only" vials. If you want a proven peptide at a lower cash price, ask a licensed provider about compounded semaglutide or tirzepatide, which are not FDA-approved.